← All Pharvaris NV filings

Pharvaris NV 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
PHVS
Pharvaris NV
20-F: Pharvaris Deucrictibant Shows Strong Phase 3 Efficacy
Pharvaris N.V. reports positive pivotal Phase 3 data for deucrictibant IR capsule in HAE on-demand treatment, with plans for a U.S. NDA submission in H1 2026.
NASDAQ
PHVS
Pharvaris NV
20-F: Pharvaris N.V. Files 20-F Annual Report, Outlines Financials and Development Pipeline
Pharvaris N.V. files its annual report, detailing its financial status and progress in developing innovative therapies for rare diseases, particularly angioedema.
NASDAQ
PHVS
Pharvaris NV
20-F: Pharvaris N.V. Files 20-F Annual Report, Providing Overview of Financials and Clinical Progress
Pharvaris N.V. releases its 20-F annual report, detailing financial results, clinical trial updates, and future strategies for its HAE treatments.